Background: Insufficient residual alveolar bone height is a common deterrent in the placement of dental implants in the posterior maxilla. The use of autografts, xenografts, allografts and alloplasts or a combination between them has been demonstrated to be effective for increasing bone height and bone volume in the deficient posterior maxilla.
Purpose: The aim of this clinical trial is to comparatively determine the density of newly formed in sinus floor augmentation bone after a 24-week healing period treatment with a new bovine xenograft.
Materials And Methods: The sinus floor was grafted with Bio-Oss® (n = 10) and Osseous® (n = 10). Histological sections were examined with a focus on the presence of connective tissue (CT) and newly formed bone (NFB). The sections were histomorphometrically evaluated and the definitive crown was inserted after 3 months.
Results: After 6 months, the mean value of new bone formation was 24.60 (±2.503), the CT was 42.60 (±4.006) and the remaining biomaterial was 25.40 (±2.547) in Bio-Oss group. In Osseous group, the mean value of new bone formation was 24.90 (±3.542), the CT was 45.70 (±7.040) and the remaining biomaterial was 22.90 (±3.247).
Conclusions: Both biomaterials afforded a favorable implant position and the prosthetic rehabilitation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cid.12289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Opioids are still being prescribed to manage acute postsurgical pain. Unnecessary opioid prescriptions can lead to addiction and death, as unused tablets are easily diverted.
Methods: To determine whether combination nonopioid analgesics are at least as good as opioid analgesics, a multisite, double-blind, randomized, stratified, noninferiority comparative effectiveness trial was conducted, which examined patient-centered outcomes after impacted mandibular third-molar extraction surgery.
Comparative Analysis of Gelatin/Polylactic Acid and Commercial PLA Membranes for Guided Bone Regeneration: A Randomized Clinical Trial.
Med Sci Monit
January 2025
Department of Oral Implantology, The Affiliated Stomatology Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Province Key Laboratory of Oral Biomedicine, Jiangxi Province Clinical Research Center for Oral Disease, Nanchang, Jiangxi, China.
BACKGROUND This study included 32 patients with single missing teeth and alveolar bone defects and aimed to compare outcomes from guided bone regeneration with a gelatin/polylactic acid (GT/PLA) barrier membrane and a Guidor® bioresorbable matrix barrier dental membrane. MATERIAL AND METHODS A total of 32 participants were recruited in the clinical study, with single missing teeth and alveolar bone defects, requiring guided bone regeneration (32 missing teeth in total). They were randomly divided into the GT/PLA membrane group (experimental) and Guidor® membrane group (control) by the envelope method (n=16).
View Article and Find Full Text PDFEvaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial.
Rheumatol Ther
January 2025
Biosplice Therapeutics, Inc., 9360 Towne Centre Dr, San Diego, CA, 92121, USA.
Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.
Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS.
View Article and Find Full Text PDFThe Agreement Between Lobar Emphysematous Destruction and Volumetric Air Trapping on CT Scan in Severe COPD Patients.
Lung
January 2025
Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!